Avadel Pharmaceuticals

#4598

Rank

$2.12B

Marketcap

Ireland

Country

Leadership team

Mr. Gregory J. Divis Jr. (CEO & Director)

Mr. Thomas S. McHugh (Sr. VP & CFO)

Mr. Richard Kim (Chief Commercial Officer)

Products/ Services

Biotechnology, Information Technology, Manufacturing, Pharmaceutical

Number of Employees

50 - 100

Headquarters

Dublin, Dublin, Ireland

Established

1990

Company Registration

SEC CIK number: 0001012477

Traded as

AVDL

Social Media

URL

https://www.avadel.com

Overview

Location

Recognition and Award

References

Summary

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

History

Avadel was founded in January 2001 through a merger of Neo Pharm International and Laboratoires Delagrange. The company identified its primary focus early on in the production of sterile injectable drugs and plans to develop additional sterile injectable and other pharmaceutical products.

Mission

Avadel develops and markets innovative products and solutions in people’s health. We are committed to providing healthcare professionals with the highest quality and most effective solutions, so that our customers can achieve healthier lives.

Vision

Our vision is to be a leading provider of healthcare products that improve the lives of individuals around the world.

Key Team

Ms. Angie Woods (VP of People & Culture)

Mr. Christian Kalita Pharm.D (Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs)

Mr. Jerad G. Seurer (Gen. Counsel & Company Sec.)

Mr. Steven G. Sullivan (VP of Sales & Marketing and Head of Commercial Operations)

Mr. Gregory J. Davis (VP of Corp. and Bus. Devel.)

Dr. Jordan S. Dubow M.D. (Consultant)

Mr. Mark W. Elrod (VP of Sales)

Recognition and Awards

Avadel has been the recipient of numerous awards, including the 2015 NASDAQ Excellence Award and the 2016 Irish Pharma Award for Innovation. The company was also recognized by the Irish government as one of the fastest growing businesses in Ireland in 2017.